|
zinc ion actions
|
agonists
|
endogenous
|
enkephaline
|
δ-receptor specific agonist
|
reduced both affinity and number of binding sites
| |
physiological concentration
|
Ogawa N. et al., 1985 [43]
|
|
exogenous
|
[3H] DAGO [([Tyr-D-Ala-Gly-Methyl-Phe-Glyol]-enkephalin
|
μ-receptor
|
reduced
| |
micromolar concentration
|
Tejwani G.A., Hanissian S.H. 1990 [42]
|
| |
μ-receptor
|
reduced
| | |
Fowler C.B. et al., 2004 [78]
|
|
[3H] DSTLE ([Tyr-D-Ser-Gly-Phe-Leu-Thr]-enkephalin)
|
δ-receptor
|
slighly reduced
| |
micromolar concentration
|
Tejwani G.A., Hanissian S.H. 1990 [42]
|
|
3H-met-enkephalinamide (2-D-ala-5-L-methionine)
|
δ-receptor
|
reduced
|
hippocampus, the cerebral cortex and the basal ganglia of the (rat)
|
endogenous concentrations
|
Stengaard-Pedersen K., 1982 [79]
|
|
[3H] EKC (ethylketocyclazocine)
|
κ-receptor
|
slighly reduced
| |
micromolar concentration
|
Tejwani G.A., Hanissian S.H. 1990 [42]
|
|
(+)-[3H]pentazocine
|
σ2-receptor
|
slighly reduced
|
hippocampus (rat)
|
milimolar concentration
|
Connor M.A., Chavkin C. 1992 [83]
|
|
antagonist
|
[3H]naloxone
|
μ-receptor
|
reduced affinity, with no effect on the number of binding sites
|
hippocampus, cortex, midbrain, striatum (rat)
|
dose-dependent manner
|
Hanissian S.H., Tejwani G.A. 1990 [85]
|
|
reduced zinc concentration compared to physiologic conditions
|
metallothionein peptide 1 (specific zinc chelator)
|
agonists
|
exogenous
|
(+)-[3H]pentazocine
|
σ2-receptor
|
non-changed
|
hippocampus (rat)
| |
Connor M.A., Chavkin C. 1992 [83]
|
|
zinc deficiency effect compared to normally-fed animals
|
antagonist
|
[3H]naloxone
|
μ-receptor
|
increased
|
isolated brain membranes (rat)
| |
Essatara M.B., 1984 [72]
|
